Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Phio Pharmaceuticals Corp PHIO

Healthcare Biotechnology
Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company. The Company's INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. It is developing therapeutics that are designed to leverage INTASYL to target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or... see more

Recent & Breaking News (NDAQ:PHIO)

Phio Pharmaceuticals Appoints Robert Bitterman as President and Chief Executive Officer

PR Newswire February 22, 2023

Phio Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

PR Newswire February 13, 2023

Phio Pharmaceuticals Announces Positive DMC Recommendation and Continued Enrollment of Advanced Melanoma Study Without Modification

PR Newswire February 10, 2023

Phio Pharmaceuticals Announces Reverse Stock Split

PR Newswire January 25, 2023

Phio Showcases Innovations in Dermatology Cancers at 2023 Dermatology Summit in San Francisco

PR Newswire January 6, 2023

Phio Pharmaceuticals Announces Regulatory Clearance of Clinical Trial With PH-762 and AgonOx's Tumor Infiltrating Lymphocytes (AGX148) to Treat Solid Tumors

PR Newswire January 6, 2023

Phio Pharmaceuticals Announces New Clinical Program to Study PH-762 for the Treatment of Cutaneous Squamous Cell Carcinoma

PR Newswire December 21, 2022

Phio Announces New Appointments to Leadership Team, Reports on Third Quarter 2022 Financial Results and Provides Business Update

PR Newswire November 10, 2022

Phio Pharmaceuticals Announces Study Results at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on November 10th and 11th

PR Newswire November 10, 2022

Phio Pharmaceuticals Announces Upcoming Presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

PR Newswire October 6, 2022

Phio Pharmaceuticals Announces Appointment of Robert Bitterman as Executive Chairman

PR Newswire September 29, 2022

Phio Pharmaceuticals Announces Preclinical Data Demonstrating PH-762 Enhances Persistence of T cells for Tumor Cell Killing as Presented by Helmholtz Munich at the 9th Immunotherapy of Cancer Conference

PR Newswire September 22, 2022

Phio Pharmaceuticals Announces Acceptance of Six Abstracts at The 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

PR Newswire September 12, 2022

Phio Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

PR Newswire August 11, 2022

Phio Pharmaceuticals Presents Study Outline of Its First Clinical Trial with PH-762 for Advanced Melanoma at the 2022 ASCO Annual Meeting

PR Newswire June 6, 2022

Phio Pharmaceuticals Presents New Data Demonstrating PH-894 Enhances Activity of HER2-CAR-T Cells at ASGCT 2022

PR Newswire May 16, 2022

Phio Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update

PR Newswire May 12, 2022

Phio Pharmaceuticals Announces Senior Leadership Personnel Change

PR Newswire May 5, 2022

Phio Pharmaceuticals Announces Trial-In-Progress Poster at ASCO 2022

PR Newswire May 3, 2022

Phio Pharmaceuticals Announces Upcoming Presentation of PH-894 Data at ASGCT 25th Annual Meeting 2022

PR Newswire May 2, 2022